KR101152470B1 - 치료제용 마이크로-입자 지방산 염 고형 투약 제형 - Google Patents

치료제용 마이크로-입자 지방산 염 고형 투약 제형 Download PDF

Info

Publication number
KR101152470B1
KR101152470B1 KR1020067002974A KR20067002974A KR101152470B1 KR 101152470 B1 KR101152470 B1 KR 101152470B1 KR 1020067002974 A KR1020067002974 A KR 1020067002974A KR 20067002974 A KR20067002974 A KR 20067002974A KR 101152470 B1 KR101152470 B1 KR 101152470B1
Authority
KR
South Korea
Prior art keywords
delete delete
pharmaceutical composition
fatty acid
acid
polypeptide drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067002974A
Other languages
English (en)
Korean (ko)
Other versions
KR20060082851A (ko
Inventor
포이에크 오파웨일
리챠드 솔테로
Original Assignee
바이오콘 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오콘 리미티드 filed Critical 바이오콘 리미티드
Publication of KR20060082851A publication Critical patent/KR20060082851A/ko
Application granted granted Critical
Publication of KR101152470B1 publication Critical patent/KR101152470B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020067002974A 2003-08-13 2004-08-13 치료제용 마이크로-입자 지방산 염 고형 투약 제형 Expired - Fee Related KR101152470B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49482103P 2003-08-13 2003-08-13
US60/494,821 2003-08-13

Publications (2)

Publication Number Publication Date
KR20060082851A KR20060082851A (ko) 2006-07-19
KR101152470B1 true KR101152470B1 (ko) 2012-06-01

Family

ID=34193244

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067002974A Expired - Fee Related KR101152470B1 (ko) 2003-08-13 2004-08-13 치료제용 마이크로-입자 지방산 염 고형 투약 제형

Country Status (12)

Country Link
US (1) US7635675B2 (https=)
EP (1) EP1660047B1 (https=)
JP (1) JP4880461B2 (https=)
KR (1) KR101152470B1 (https=)
CN (2) CN102552917A (https=)
AU (1) AU2004264958B2 (https=)
CA (1) CA2535013C (https=)
DK (1) DK1660047T3 (https=)
ES (1) ES2445947T3 (https=)
PL (1) PL1660047T3 (https=)
PT (1) PT1660047E (https=)
WO (1) WO2005016312A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090281023A9 (en) * 2001-06-04 2009-11-12 Nobex Corporation Mixtures Of Calcitonin Drug-Oligomer Conjugates And Methods Of Use In Pain Treatment
RU2527893C2 (ru) * 2004-07-19 2014-09-10 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
WO2007006320A1 (en) * 2005-07-12 2007-01-18 Sherine Hassan Abbas Helmy Drinkable oral insulin liquid and capsules
ES2546016T3 (es) * 2005-10-13 2015-09-17 Biocon Limited Procedimiento para la preparación de conjugados de insulina
RU2524150C2 (ru) 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
RU2453332C2 (ru) 2007-10-16 2012-06-20 Байокон Лимитид Твердая фармацевтическая композиция (варианты) и способ контроля концентрации глюкозы с ее помощью, способ получения твердой фармацевтической композиции (варианты), таблетка (варианты) и способ получения амфорных частиц
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
RU2517135C2 (ru) * 2008-05-07 2014-05-27 Меррион Рисерч Iii Лимитед Композиции пептидов и способы их получения
EP2334335A1 (en) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of cd-np peptides
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
CN103596584B (zh) 2011-06-15 2016-12-14 诺沃—诺迪斯克有限公司 多取代的胰岛素
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
JP6499184B2 (ja) 2013-10-07 2019-04-10 ノヴォ ノルディスク アー／エス インスリン類似体の新規な誘導体
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
WO2016119854A1 (en) * 2015-01-29 2016-08-04 Novo Nordisk A/S Pharmaceutical composition for oral insulin administration comprising a tablet core and a polyvinyl alcohol coating
US9907323B2 (en) 2015-09-25 2018-03-06 Mead Johnson Nutrition Co. Infant formula tablets
PE20210857A1 (es) 2016-12-16 2021-05-18 Novo Nordisk As Composiciones farmaceuticas que contienen insulina

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020187536A1 (en) * 1995-06-29 2002-12-12 Kulkarni Sunanda R. Stable lactase tablets and methods of production

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US187536A (en) * 1877-02-20 Improvement in discharge-nozzles for graiw-eievators
US3957662A (en) * 1972-08-08 1976-05-18 Hoffmann-La Roche Inc. Pharmaceutical lubricants
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS597683B2 (ja) 1976-06-23 1984-02-20 山之内製薬株式会社 顆粒剤
JPS55153712A (en) 1979-05-18 1980-11-29 Kao Corp Insulin pharmaceutical preparation and its production
JPS56131514A (en) 1980-03-17 1981-10-15 Nissan Chem Ind Ltd Ketoprofen composition for rectum administration
JPS5764610A (en) 1980-10-08 1982-04-19 Fujisawa Pharmaceut Co Ltd Pharmaceutical for rectal administration
US4310543A (en) 1980-10-09 1982-01-12 Hoffmann-La Roche Inc. Prostaglandin compositions
JPS5764609A (en) 1980-10-09 1982-04-19 Nissan Chem Ind Ltd Cyclophosphamide composition for rectal administration
JPS57158719A (en) 1981-03-24 1982-09-30 Fujisawa Pharmaceut Co Ltd Rectal administration pharmaceutical
JPS5813508A (ja) 1981-07-14 1983-01-26 Taiho Yakuhin Kogyo Kk ポリグリセロール飽和脂肪酸エステルを含む経口薬剤組成物
JPS58206515A (ja) 1982-05-25 1983-12-01 Fujisawa Pharmaceut Co Ltd 硬カプセル剤
US4704284A (en) 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
JPS5951223A (ja) 1982-09-17 1984-03-24 Sumitomo Chem Co Ltd 製剤組成物
US4439420A (en) * 1982-11-16 1984-03-27 Ethicon, Inc. Absorbable hemostatic composition
JPS59148735A (ja) 1983-02-14 1984-08-25 Fujisawa Pharmaceut Co Ltd ユビデカレノン組成物
JPS59175433A (ja) 1983-03-24 1984-10-04 Kanegafuchi Chem Ind Co Ltd Ｓ−アデノシル−ｌ−メチオニン含有組成物
JPS60146825A (ja) 1984-01-10 1985-08-02 Asahi Chem Ind Co Ltd 経口医薬製剤
JPS60214735A (ja) 1984-04-06 1985-10-28 Morishita Seiyaku Kk 脂肪酸の直腸投与組成物
JPS60218318A (ja) 1984-04-16 1985-11-01 Ss Pharmaceut Co Ltd 軟カプセル充填用組成物
JPS6112632A (ja) 1984-06-27 1986-01-21 Eisai Co Ltd 脂溶性薬剤含有組成物
JPS6176416A (ja) 1984-09-20 1986-04-18 Fujimoto Seiyaku Kk 活性型ビタミンｄ↓３誘導体のカプセル剤用組成物
JPS61233625A (ja) 1985-04-08 1986-10-17 Sanraku Inc γ−リノレン酸含有油脂組成物
NL8600050A (nl) 1986-01-13 1987-08-03 Sanico Nv Farmaceutisch preparaat met vertraagde afgifte van het werkzame bestanddeel en werkwijze voor de bereiding er van.
ZA87279B (en) 1986-01-17 1987-09-30 Chugai Pharmaceutical Co Ltd Method for production of stable nicorandil preparation
US5140021A (en) 1986-04-16 1992-08-18 Genesis Systems Corporation Method and dosage form for treatment of premenstrual syndrome
JPS6317821A (ja) 1986-07-11 1988-01-25 Taisho Pharmaceut Co Ltd 矯味経口製剤
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
DK130287D0 (da) * 1987-03-13 1987-03-13 Benzon As Alfred Oralt praeparat
JPS63280017A (ja) 1987-05-13 1988-11-17 R P Shiila- Kk 軟カプセル用の皮膜組成物
JPS6419018A (en) 1987-07-14 1989-01-23 Nippon Oils & Fats Co Ltd Cholesterol depressing agent
US4900734A (en) 1987-08-27 1990-02-13 Maxson Wayne S Novel pharmaceutical composition containing estradiol and progesterone for oral administration
CA1321994C (en) 1987-10-28 1993-09-07 Reid Von Borstel Acylated uridine and cytidine and uses thereof
JPH01224315A (ja) 1988-03-04 1989-09-07 Green Cross Corp:The 医薬組成物
JP2677613B2 (ja) 1988-06-24 1997-11-17 エーザイ株式会社 ビタミンｅ又はその誘導体の吸収促進組成物
US4908210A (en) 1988-10-28 1990-03-13 Eastman Kodak Company Lactylic salt tablet formulations and tablets
JP2818220B2 (ja) 1988-11-04 1998-10-30 フロイント産業株式会社 食品用の含水有機溶剤抽出物含有組成物および医薬用の含水有機溶剤抽出物含有組成物、並びにそれらの製造方法
GB8904182D0 (en) 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
FI96169C (fi) 1989-07-10 1996-05-27 Eisai Co Ltd Menetelmä polyprenyyliyhdistettä sisältävän farmaseuttisen koostumuksen valmistamiseksi
US5532002A (en) 1989-08-17 1996-07-02 Cortecs Limited Gelatin pharmaceutical formulations
JPH03200715A (ja) 1989-12-27 1991-09-02 Lion Corp 口腔用組成物
JP2896185B2 (ja) 1990-02-27 1999-05-31 東京田辺製薬株式会社 胆汁酸内用液剤およびその製造方法
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
WO1992021348A1 (en) 1991-06-03 1992-12-10 Merck Sharp & Dohme Limited Pharmaceutical formulations of a benzodiazepine
JPH08505367A (ja) 1992-10-16 1996-06-11 スミスクライン・ビーチャム・コーポレイション 医薬用エマルジョン組成物
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
AU7113594A (en) * 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
FR2710535B1 (fr) 1993-09-30 1995-11-24 Gattefosse Ets Sa Composition à usage pharmaceutique ou cosmétique apte à former une microémulsion.
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
GB9325395D0 (en) 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
JPH07215883A (ja) 1994-02-01 1995-08-15 Shiyugaa Redei:Kk 冷凍保存可能な高濃度ロイヤルゼリーソフトカプセル製剤
JP3429065B2 (ja) 1994-06-21 2003-07-22 サンスター株式会社 口腔用液体組成物
US6165976A (en) * 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
SK164796A3 (en) 1994-11-03 1997-06-04 Dresden Arzneimittel Novel cyclosporine preparation forms for oral administration of and process for producing them
KR0167613B1 (ko) 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
EP0760237A1 (en) 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
FR2748209B1 (fr) 1996-05-06 1998-06-05 Adir Composition pharmaceutique a base de matrices lipophiles stabilisees pour la liberation controlee de principes actifs
SK285019B6 (sk) 1997-01-30 2006-04-06 Novartis Ag Tvrdá želatínová tobolka
US5900402A (en) 1997-05-29 1999-05-04 Enzon, Inc. Method of reducing side effects associated with administration of oxygen-carrying proteins
GB9717428D0 (en) 1997-08-19 1997-10-22 Glaxo Group Ltd Pharmaceutical composition
US6054480A (en) 1997-09-18 2000-04-25 Nectra, Inc. Fatty acids as a diet supplement
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6214330B1 (en) 1998-07-13 2001-04-10 Enzon, Inc. Coumarin and related aromatic-based polymeric prodrugs
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
JP2000095676A (ja) 1998-09-21 2000-04-04 Tokai Capsule Kk ビタミンｂ１２含有ソフトカプセル剤
HK1043945B (zh) 1999-02-23 2005-02-08 株式会社柳韩洋行 含氯雷他定和伪麻黄碱的药物胶囊组合物
EP1156812A4 (en) * 1999-02-23 2004-09-29 Isis Pharmaceuticals Inc MULTIPARTICULAR FORMULATION
CN1167462C (zh) 1999-03-09 2004-09-22 杭州华东医药集团生物工程研究所有限公司 一种含环孢素的药物组合物
JP4538858B2 (ja) * 1999-03-09 2010-09-08 日油株式会社 滑沢剤およびそれを用いた固形製剤
JP3278427B2 (ja) 1999-03-26 2002-04-30 有限会社ゴトーコーポレーション カプセル剤の製造方法
GB9907715D0 (en) 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
TWI232761B (en) 2000-07-01 2005-05-21 Pharmaceutical Ind Tech & Dev Capsule preparation for oral administration and the preparation method thereof
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6720002B2 (en) 2001-07-20 2004-04-13 R.P. Scherer Technologies, Inc. Antihistamine formulations for soft capsule dosage forms
KR100425755B1 (ko) 2001-08-27 2004-04-03 주식회사 원진신약 이트라코나졸을 함유하는 조성물 및 그 제조방법
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
GB2391473B (en) 2002-08-02 2004-07-07 Satishchandra Punambhai Patel Pharmaceutical compositions
WO2004047871A2 (en) 2002-11-26 2004-06-10 Nobex Corporation Modified naturetic compounds, conjugates, and uses thereof
US20040115226A1 (en) 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
KR100525234B1 (ko) 2003-02-19 2005-10-28 한국유나이티드제약 주식회사 사이클로스포린 함유 연질캅셀제 및 그 제조방법
WO2005004919A2 (en) 2003-07-02 2005-01-20 Eurand, Inc. Extended release systems for macrolide antibiotics
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
WO2005089714A1 (ja) 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited エマルション安定化製剤
CA2595116A1 (en) 2004-04-28 2005-11-10 Procarrier, Inc. Oral formulation for delivery of poorly absorbed drugs
WO2005115341A2 (en) 2004-05-27 2005-12-08 Advanced Bionutrition Corporation Microparticles for oral delivery

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020187536A1 (en) * 1995-06-29 2002-12-12 Kulkarni Sunanda R. Stable lactase tablets and methods of production

Also Published As

Publication number Publication date
JP4880461B2 (ja) 2012-02-22
AU2004264958A1 (en) 2005-02-24
PL1660047T3 (pl) 2014-05-30
ES2445947T3 (es) 2014-03-06
US7635675B2 (en) 2009-12-22
US20050095216A1 (en) 2005-05-05
CN1863510A (zh) 2006-11-15
CN102552917A (zh) 2012-07-11
CA2535013A1 (en) 2005-02-24
EP1660047B1 (en) 2013-11-27
EP1660047A1 (en) 2006-05-31
AU2004264958B2 (en) 2010-04-15
JP2007502303A (ja) 2007-02-08
CA2535013C (en) 2013-02-12
WO2005016312A1 (en) 2005-02-24
DK1660047T3 (en) 2014-03-10
KR20060082851A (ko) 2006-07-19
PT1660047E (pt) 2014-02-27

Similar Documents

Publication Publication Date Title
KR101152470B1 (ko) 치료제용 마이크로-입자 지방산 염 고형 투약 제형
RU2527893C2 (ru) Инсулин-олигомерные конъюгаты, их препараты и применения
AU625498B2 (en) Pharmaceutical formulations
RU2368390C2 (ru) Применение кальцитонина при остеоартрите
CN101903014B (zh) 固体内核中包含生长激素的固体脂质微囊
WO2002020037A1 (fr) Composition pharmaceutique a administration orale liberee au niveau colique
JP2017061572A (ja) Ｒａの処置のためのカルシトニンの使用
WO2007036946A1 (en) Compositions for enhanced absorption of biologically active agents
JP2013501043A (ja) 経口投与可能な医薬製剤
JP2013501043A5 (https=)
HK1152229B (en) Use of calcitonin in osteoarthritis
KR20170093332A (ko) 경구투여가능한 인슐린 함유 약제학적 조성물
HK1089935B (en) Use of calcitonin in osteoarthritis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

FPAY Annual fee payment

Payment date: 20150430

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20160427

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20170504

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20180427

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20190429

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220526

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220526